B244 for Eczema Itch: What the 547-Adult Trial Measured
Dr. Arsy Editorial Team · November 9, 2026
A controlled eczema trial reported a statistically significant improvement in itch, but the size and duration of the result matter. Researchers enrolled 547 adults to compare the investigational live-bacteria spray B244 with its vehicle for four weeks. The trial measured itch—not a cure, and not an effect of Dr. Arsy #003. [3]
Why the trial focused on itch
Participants were 18 to 65 years old, with mild-to-moderate atopic dermatitis and moderate-to-severe itching. At 56 U.S. sites, they were randomized to one of two concentrations of B244 or a vehicle spray, used twice daily for four weeks. The primary outcome was the change in worst-itch numeric rating, assessed on a scale from zero to ten. [3]
In the paper's summary, average itch fell by about 2.8 points in the B244 groups compared with 2.1 points with vehicle. That is a difference of roughly 0.7 points between groups, not a 34% cure rate or a promise that every participant experienced the same relief. Both doses were reported statistically significant against vehicle; individual experience and the importance of the difference can vary. [3]
| What was measured | What it does not establish |
|---|---|
| Average worst-itch score at four weeks | Long-term control, complete clearance or a result in babies. |
| Two experimental concentrations | That a product with different microbes will behave the same way. |
| Short-term adverse events | All possible harms with prolonged or repeated use. |
What happened with side effects?
In the safety groups, treatment-emergent adverse events were reported by 33 of 180 participants in the lower-dose group, 29 of 180 in the higher-dose group and 17 of 186 in the vehicle group. The report described the events as generally mild and transient and reported no serious adverse events. A treatment-emergent event is an event occurring during the study; that term alone does not establish that the spray caused it. The study was funded by its developer. [3]
Different microbes, different evidence
B244 should not be grouped as interchangeable with every probiotic or bacterial ingredient. The S. hominis A9 phase 1 trial centered on short-term safety and microbial measures, while the larger FB-401 study did not establish superiority over its placebo. Early Roseomonas studies had no blinded placebo comparison. These are separate products and questions. [4][5][6][7]
Other controlled studies examined bacterial extracts, an antimicrobial fragrance, and experimental enzymes, sometimes finding no difference from the comparator. Together they show why the formulation, patient population, endpoint and comparison matter more than a broad “microbiome” label. [1][2][8][9][10]
Questions to bring to a clinician
- What is causing the itch, and is the current treatment plan controlling inflammation?
- What outcome did the study measure: itch, skin appearance, sleep or bacterial counts?
- Was the treatment evaluated in people of my age, and for how long?
- If a product is experimental, what evidence exists beyond the published trial?
Persistent sleep loss, worsening discomfort or signs of infection deserve an assessment. Do not replace prescribed care with a homemade microbial mixture or an unrelated cosmetic product. [12][13][19][20]
Read the wider evidence in context
Skin-microbiome research includes studies of live organisms, inactive bacterial material, proteins targeting bacteria, and ordinary skin-care products. Clinical scores, itch reports, skin barrier tests and bacterial measures do not answer the same question. Guidelines support individualized eczema care and moisturization; studies of other formulas cannot be transferred to a different product. [11][12][13][14][15][16][17][18][19][20]
Dr. Arsy #003 in a daily routine
Explore Dr. Arsy™ Hydration Recovery Moisturizer #003, 4 oz, a fragrance-free moisturizer for dry, sensitive and eczema-prone skin. The studies discussed here did not test #003 and do not show that it alters the microbiome, treats eczema or treats infection. For babies, ask the child's clinician before choosing skin-care products.
Related reading
- Endolysin XZ.700 for Eczema: What a 39-Person Study Actually Found
- Staphylococcus hominis A9 and Eczema: Why a Safety Trial Was Not Proof of Clearance
- Can a Moisturizer Change the Eczema Microbiome? A 7-Day Study With 22 Analyzed
- A Nature-Derived Microbial Lotion for Eczema: Why a 28-Day Signal Needs a Placebo
- Microbiome treatments: why later trials matter
- Eczema or skin infection? Warning signs and care
Research and clinical references
- XZ.700: first-in-human randomized endolysin study.
- SA.100: vehicle-controlled endolysin trial.
- B244: phase 2b ammonia-oxidizing bacteria trial.
- Staphylococcus hominis A9 phase 1 clinical trial.
- FB-401: placebo-controlled Roseomonas trial.
- First-in-human Roseomonas mucosa research.
- Roseomonas mucosa research in children.
- Lactobacillus lactis lysate: placebo-controlled pilot.
- Moisturizer and farnesol: skin-microbiome experiment.
- Inactivated environmental microbial extract: pilot trial.
- Staphylococcus aureus and eczema severity: systematic review.
- International Eczema Council: skin bacteria and infection.
- Infectious complications of atopic dermatitis.
- Topical niclosamide and the eczema skin microbiome.
- Isosorbide diesters and the pediatric skin microbiome.
- Antimicrobial-corticosteroid combinations and skin microbiome.
- Systemic eczema therapies and skin bacteria: pilot research.
- Emollients and skin-barrier function: systematic review.
- AAD guideline: pediatric eczema management.
- AAD guideline: adult eczema topical management.
Educational information; not a diagnosis or individual medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.